title: NICE guidance on radium-223 dichloride for hormone-relapsed prostate cancer with bone metastases.
authors.affiliation: National Institute for Health and Care Excellence, Manchester M1 4BT, UK. Electronic address: nwamaka.umeweni@nice.org.uk.
authors.forename: Nwamaka
authors.initials: N
authors.lastname: Umeweni
authors.affiliation: National Institute for Health and Care Excellence, Manchester M1 4BT, UK.
authors.forename: Helen
authors.initials: H
authors.lastname: Knight
authors.affiliation: National Institute for Health and Care Excellence, Manchester M1 4BT, UK.
authors.forename: Gary
authors.initials: G
authors.lastname: McVeigh
mesh_terms: D000368:Aged; D001859:Bone Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000628:therapy; D017410:Practice Guidelines as Topic; D011379:Prognosis; D064129:Prostatic Neoplasms, Castration-Resistant / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D011868:Radioisotopes; D011883:Radium; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D011868:Radioisotopes; C581106:radium Ra 223 dichloride; D011883:Radium